Long-Term Use of Tirzepatide: What Happens After 1, 2, and 5 Years?

As tirzepatide becomes more widely used, questions about long-term outcomes are increasingly important. Here's what the data shows.

Long-Term Efficacy Data

SURMOUNT-4: Withdrawal Study

This critical trial examined what happens when tirzepatide is stopped:

• Patients first received tirzepatide for 36 weeks (achieving ~21% weight loss)
• Then randomized to continue tirzepatide or switch to placebo for 52 additional weeks

Results:

• Continued tirzepatide: Maintained weight loss and lost an additional ~5%
• Switched to placebo: Regained approximately 14% of body weight (about half of what was lost)
• After 88 total weeks, placebo group still weighed less than baseline

SURPASS-4: Long-term Diabetes Data

• 104-week data showed sustained HbA1c reduction
• Weight loss plateaued but was maintained
• No new safety signals with longer treatment

What Happens When You Stop?

Weight Regain

• Most patients regain some weight after discontinuation
• The extent of regain varies (typically 50-67% of lost weight over 1-2 years)
• Lifestyle changes made during treatment can mitigate regain
• This mirrors what happens with all anti-obesity medications

Blood Sugar Changes

• HbA1c tends to rise after stopping
• May not return to pre-treatment levels if lifestyle changes are maintained
• Some patients may need to restart or switch to another therapy

Why Regain Occurs

• Obesity is a chronic disease requiring ongoing treatment
• Metabolic adaptations persist (reduced metabolic rate)
• Hormonal changes drive hunger and weight regain
• This is not a "willpower" issue — it's biology

Long-Term Safety Considerations

Thyroid Monitoring

• Boxed warning about thyroid C-cell tumors (based on rodent studies)
• No confirmed cases in humans to date
• Regular thyroid monitoring recommended

Pancreatic Health

• Ongoing surveillance for pancreatitis risk
• Low incidence in clinical trials
• Report persistent abdominal pain immediately

Bone Health

• Rapid weight loss can affect bone density
• Weight-bearing exercise and calcium/vitamin D supplementation recommended
• DXA scans may be appropriate for long-term users

Gallbladder Health

• Increased gallstone risk with rapid weight loss
• Risk decreases as weight stabilizes
• Ursodiol prophylaxis may be considered for high-risk patients

The Case for Long-Term Treatment

Most obesity medicine experts view tirzepatide as a chronic treatment, similar to medications for hypertension or high cholesterol:

1. Obesity is a chronic, relapsing disease
2. The biological drivers of weight regain persist
3. Ongoing treatment maintains health benefits
4. Risk-benefit ratio generally favors continued therapy
5. Cost and access remain the primary barriers to long-term use